NEW YORK, NY / ACCESSWIRE / May 2, 2022 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bausch Health Companies f/k/a Valeant ("Bausch" or "the Company") (NYSE/TSX: BHC). Investors who purchased Bausch securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/bhc.
The investigation concerns whether Bausch and certain of its officers and/or directors have engaged in corporate wrongdoing.
On April 20, 2022, Bausch launched an initial public offering and Eye-Care spinoff, offering 35 million shares at between $21 and $24 per share, with a 30-day underwriter option for up to 5.25 million additional shares. The company will list shares under the ticker symbol BLCO on the New York Stock Exchange and the Toronto Stock Exchange.
If you are aware of any facts relating to this investigation or purchased Bausch shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/bhc. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC